title: New medications which decrease levothyroxine absorption.
abstract: OBJECTIVE
  Medications may sometimes interfere with the intestinal absorption of levothyroxine, primarily by forming an insoluble complex with the thyroid hormone in the intestinal lumen. The goal of this study was to examine the acute effects of three previously unstudied medications on levothyroxine absorption.
  
  
  METHODS
  We studied the effects of three medications on thyroxine absorption in seven normal volunteers. On each study day, the subjects ingested 1 mg levothyroxine sodium, either taken separately or co-administered with sevelamer hydrochloride (Renagel, a phosphate-binding medication used in the treatment of hyperphosphatemia), chromium picolinate (an over-the-counter nutritional supplement), or ezetimibe (Zetia, a drug used in the treatment of hypercholesterolemia). Serum thyroxine was measured at intervals over a 6-hour period following drug ingestion.
  
  
  RESULTS
  Sevelamer hydrochloride and chromium picolinate each significantly (p < 0.05) decreased the area under the serum thyroxine concentration curve, while ezetimibe had no effect.
  
  
  CONCLUSIONS
  Hypothyroid patients taking sevelamer hydrochloride or chromium picolinate should be advised to separate the time of ingestion of these drugs from their thyroid hormone preparation by several hours.
authors.affiliation: Endocrinology Division, Department of Medicine, Stony Brook University School of Medicine, Stony Brook, New York 11794-8154, USA.
authors.forename: Jennifer
authors.initials: J
authors.lastname: John-Kalarickal
authors.forename: Gwen
authors.initials: G
authors.lastname: Pearlman
authors.forename: Harold E
authors.initials: HE
authors.lastname: Carlson
mesh_terms: D000328:Adult; D000924:Anticholesteremic Agents / Q000008:administration & dosage; D001384:Azetidines / Q000008:administration & dosage*; D002614:Chelating Agents / Q000008:administration & dosage; D004347:Drug Interactions; D000069438:Ezetimibe; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy; D007037:Hypothyroidism / Q000188:drug therapy; D007408:Intestinal Absorption / Q000187:drug effects*; D007502:Iron Chelating Agents / Q000008:administration & dosage; D008297:Male; D010848:Picolinic Acids / Q000008:administration & dosage*; D011073:Polyamines / Q000008:administration & dosage*; D000069603:Sevelamer; D013974:Thyroxine / Q000097:blood / Q000493:pharmacokinetics*
chemical_list: D000924:Anticholesteremic Agents; D001384:Azetidines; D002614:Chelating Agents; D007502:Iron Chelating Agents; D010848:Picolinic Acids; D011073:Polyamines; D000069603:Sevelamer; D000069438:Ezetimibe; D013974:Thyroxine; C030614:picolinic acid